Self-proning in COVID-19 patients on low-flow oxygen therapy: a cluster randomised controlled trial.
Journal
ERJ open research
ISSN: 2312-0541
Titre abrégé: ERJ Open Res
Pays: England
ID NLM: 101671641
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
received:
28
09
2020
accepted:
22
01
2021
entrez:
15
3
2021
pubmed:
16
3
2021
medline:
16
3
2021
Statut:
epublish
Résumé
Prone positioning as a complement to oxygen therapy to treat hypoxaemia in coronavirus disease 2019 (COVID-19) pneumonia in spontaneously breathing patients has been widely adopted, despite a lack of evidence for its benefit. We tested the hypothesis that a simple incentive to self-prone for a maximum of 12 h per day would decrease oxygen needs in patients admitted to the ward for COVID-19 pneumonia on low-flow oxygen therapy. 27 patients with confirmed COVID-19 pneumonia admitted to Geneva University Hospitals were included in the study. 10 patients were randomised to self-prone positioning and 17 to usual care. Oxygen needs assessed by oxygen flow on nasal cannula at inclusion were similar between groups. 24 h after starting the intervention, the median (interquartile range (IQR)) oxygen flow was 1.0 (0.1-2.9) L·min Self-prone positioning in patients with COVID-19 pneumonia requiring low-flow oxygen therapy resulted in a clinically meaningful reduction of oxygen flow, but without reaching statistical significance.
Identifiants
pubmed: 33718487
doi: 10.1183/23120541.00692-2020
pii: 00692-2020
pmc: PMC7869594
pii:
doi:
Types de publication
Journal Article
Langues
eng
Informations de copyright
©The authors 2021.
Déclaration de conflit d'intérêts
Conflict of interest: A. Kharat has nothing to disclose. Conflict of interest: E. Dupuis-Lozeron has nothing to disclose. Conflict of interest: C. Cantero has nothing to disclose. Conflict of interest: C. Marti has nothing to disclose. Conflict of interest: O. Grosgurin has nothing to disclose. Conflict of interest: S. Lolachi has nothing to disclose. Conflict of interest: F. Lador has nothing to disclose. Conflict of interest: J. Plojoux has nothing to disclose. Conflict of interest: J-P. Janssens has nothing to disclose. Conflict of interest: P.M. Soccal has nothing to disclose. Conflict of interest: D. Adler has nothing to disclose.
Références
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
N Engl J Med. 2013 Jun 6;368(23):2159-68
pubmed: 23688302
Thorax. 2020 Oct;75(10):833-834
pubmed: 32546571
JAMA. 2020 May 12;323(18):1839-1841
pubmed: 32215647
Crit Care. 2020 Mar 23;24(1):114
pubmed: 32204726
JAMA. 2020 Jun 9;323(22):2265-2267
pubmed: 32412579
Am J Respir Crit Care Med. 2017 May 1;195(9):1253-1263
pubmed: 28459336
Eur Respir J. 2002 Oct;20(4):1017-28
pubmed: 12412699
JAMA. 2020 May 12;323(18):1824-1836
pubmed: 32282022
Lancet Respir Med. 2020 May;8(5):475-481
pubmed: 32105632
Chest. 2017 Jan;151(1):215-224
pubmed: 27400909
JAMA. 2020 Jun 9;323(22):2338-2340
pubmed: 32412606
J Crit Care. 2015 Dec;30(6):1390-4
pubmed: 26271685
JAMA. 2020 Jun 9;323(22):2336-2338
pubmed: 32412581
Lancet Respir Med. 2020 Aug;8(8):765-774
pubmed: 32569585
Acad Emerg Med. 2020 May;27(5):375-378
pubmed: 32320506
J Appl Physiol (1985). 1991 Aug;71(2):620-9
pubmed: 1938736
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
JAMA. 2020 Apr 28;323(16):1545-1546
pubmed: 32167538
Crit Care. 2020 Jan 30;24(1):28
pubmed: 32000806
N Engl J Med. 2010 Sep 16;363(12):1107-16
pubmed: 20843245